Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer
The estrogen receptor-α (ER-α) is a key driver of breast cancer (BC) and the ER-antagonist, tamoxifen, is a central pillar of BC treatment. However, cross-talk between ER-α, other hormone and growth factor receptors enables development of de novo resistance to tamoxifen. Herein, we mechanistically d...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Jezik: | English |
Izdano: |
Elsevier
2023-07-01
|
Serija: | Pharmacological Research |
Teme: | |
Online dostop: | http://www.sciencedirect.com/science/article/pii/S1043661823001627 |